Key facts
- This page summarizes Yehuda Eliya's Form 4 filing for Raphael Pharmaceutical Inc. (RAPH).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 12 Mar 2025, 19:51.
Yehuda Eliya - 12 May 2022 Form 4 Insider Report for Raphael Pharmaceutical Inc. (RAPH)
- Reporting relationship
- Director
- Issuer ticker
- RAPH
- Reported as of
- 12 May 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Mar 2025, 19:51:29 UTC
- Prior SEC filing
- 19 Jan 2022
- Next SEC filing
- 13 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Yehuda Eliya
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Yehuda Eliya filed Form 4 for Raphael Pharmaceutical Inc. (RAPH) on 12 Mar 2025.
Change
- Previous filing in this sequence was filed on 19 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RAPH
transaction
Derivative
Warrant to purchase Common Stock
Award
- Transaction value
- $0
- Shares
- +200,000
- Change %
- Price
- $0.000000
- Shares after
- 200,000
- Date
- 10 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,000
- Exercise price
- $1.00
- Footnotes
- F1
RAPH
transaction
Derivative
Warrant to purchase Common Stock
Expiration of short derivative position
- Transaction value
- $0
- Shares
- -202,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 12 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 202,000
- Exercise price
- $1.12
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
200,000 warrants to purchase Common Stock of the issuer were received as compensation for the reporting person's service as a director of the issuer's board of directors pursuant to a service agreement by and between the issuer and the reporting person, entered on March 10, 2025. The Warrants are exercisable immediately and will expire on March 10, 2026.
Footnote F2
202,000 warrants to purchase Common Stock of the issuer expired on May 12, 2024, and are no longer beneficially owned by the reporting person.